Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 1

Status

Completed 5

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Conditions

Myasthenia Gravis 5

Interventions

rozanolixizumab 5zilucoplan 4eculizumab 4efgartigimod alfa 3Rituximab 2Prednisone 2Amifampridine 2thymoglobulin 1satralizumab 1rhoA GTP-Binding Protein 1ravulizumab 1iscalimab 1inebilizumab 1gamma-Globulins 1Thymectomy 1Sugars 1Steroids 1Sodium Chloride 1Robotic Surgical Procedures 1Prednisolone 1Methylprednisolone 1Methotrexate 1Mesna 1Hizentra 1Hematopoietic Stem Cell Transplantation 1Granulocyte Colony-Stimulating Factor 1Fluid Therapy 1Cyclophosphamide 1Acupuncture Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Has results × Myasthenia Gravis × rozanolixizumab × Clear all
NCT03971422 2025-12-24

A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

UCB Pharma

Phase 3 Completed
200 enrolled 20 charts

Myasthenia Gravis

NCT05681715 2025-11-06

A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)

UCB Pharma

Phase 3 Completed
62 enrolled 11 charts

Myasthenia Gravis

NCT04650854 2025-04-18

A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis

UCB Pharma

Phase 3 Completed
165 enrolled 21 charts

Myasthenia Gravis

NCT04124965 2023-09-05

A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

UCB Pharma

Phase 3 Completed
71 enrolled 15 charts

Myasthenia Gravis

NCT03052751 2021-08-03

Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis

UCB Pharma

Phase 2 Completed
43 enrolled 12 charts

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡